Unresectable Gastrointestinal Neuroendocrine Liver Metastases Treated by Liver-Directed Therapies

#1047

Introduction: Hepatic metastases develop in 85% of patients with GI neuroendocrine tumors. Liver-directed therapies allows for manageable microinvasive treatments able to improve the benefit and reduce the toxicity.

Aim(s): This study aimed to assess the feasibility, safety, efficacy and prognostic factors in patients with unresectable GI neuroendocrine liver metastases treated by liver-directed therapies including TACE and RFA.

Materials and methods: 24 patients (5 women) aged 28 to 77 years(mean age:57Y) histologically diagnosed GI NET-LM (14 cases were synchronous and 1 functioning tumor was gastrinoma )who were performed loco-regional therapies in our hospital from Jun 2004 to sep 2014 were analysed.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Liu L, Xin B, Ji y, Yan z, Lou w,

Keywords: neuroendocrine,TACE,RFA,liver metastases, liver-directed therapy,